trial

Risperidone and Desipramine in Alcohol Use and Schizophrenia

NCTId NCT01411085
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 12 (actual)
Sponsored by Dartmouth-Hitchcock Medical Center
Primary completion 2014-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
12 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2011-12
Primary completion
2014-08
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Risperidone

Sponsors

Dartmouth-Hitchcock Medical CenterLead Sponsor
University of South CarolinaCollaborator
University of Massachusetts, WorcesterCollaborator
Michigan State UniversityCollaborator

Investigators

1
Alan I. Green, MDPrincipal Investigator

Sites

4 total
Worcester, United StatesGrand Rapids, United StatesLebanon, United StatesColumbia, United States

Linked catalysts

1
Risperidone and Desipramine in Alcohol Use and Schizophrenia — primary completion2014-08

Facts & assertions

4 sourced
Enrollment
12
Phase
PHASE2
Primary Completion Date
2014-08
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
Dartmouth-Hitchcock Medical Center
company
collaborator
University of South Carolina
company
University of Massachusetts, Worcester
company
indication
Alcoholism
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Alan I. Green, MD
person